Latest Insider Transactions at Myovant Sciences Ltd. (MYOV)
This section provides a real-time view of insider transactions for Myovant Sciences Ltd. (MYOV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Myovant Sciences Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Myovant Sciences Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
2,436
-1.39%
|
$31,668
$13.78 P/Share
|
|
Mar 01
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,362
-0.83%
|
$17,706
$13.35 P/Share
|
|
Jan 19
2022
|
David C Marek Principal Executive Officer |
SELL
Open market or private sale
|
Direct |
19,882
-5.56%
|
$278,348
$14.68 P/Share
|
|
Jan 04
2022
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,271
-1.36%
|
$36,336
$16.27 P/Share
|
|
Jan 04
2022
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
4,475
-2.49%
|
$71,600
$16.27 P/Share
|
|
Nov 29
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,978
-1.17%
|
$37,582
$19.3 P/Share
|
|
Nov 04
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,100
-1.81%
|
$74,400
$24.02 P/Share
|
|
Nov 04
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+1.77%
|
$21,700
$7.78 P/Share
|
|
Nov 03
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
700
-0.41%
|
$16,800
$24.0 P/Share
|
|
Nov 03
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+0.41%
|
$4,900
$7.78 P/Share
|
|
Oct 05
2021
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
6,671
-3.58%
|
$140,091
$21.62 P/Share
|
|
Oct 05
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,738
-1.6%
|
$57,498
$21.62 P/Share
|
|
Sep 28
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,677
+0.04%
|
$454,894
$22.85 P/Share
|
|
Sep 27
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,000
-3.93%
|
$168,000
$24.32 P/Share
|
|
Sep 27
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+3.78%
|
$49,000
$7.78 P/Share
|
|
Sep 27
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
48,000
+0.05%
|
$1,152,000
$24.53 P/Share
|
|
Sep 24
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
36,000
+0.07%
|
$828,000
$23.4 P/Share
|
|
Sep 23
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
54,778
+0.05%
|
$1,259,894
$23.25 P/Share
|
|
Sep 22
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
84,018
+0.17%
|
$1,764,378
$21.96 P/Share
|
|
Sep 21
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
43,000
+0.09%
|
$946,000
$22.48 P/Share
|
|
Sep 20
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
38,273
+0.08%
|
$842,006
$22.1 P/Share
|
|
Sep 17
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,913
+0.08%
|
$834,086
$22.79 P/Share
|
|
Sep 16
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.1%
|
$1,050,000
$21.75 P/Share
|
|
Sep 15
2021
|
Uneek Mehra Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,069
+50.0%
|
-
|
|
Sep 15
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
89,864
+0.18%
|
$1,887,144
$21.98 P/Share
|
|
Sep 14
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
71,300
+0.07%
|
$1,568,600
$22.4 P/Share
|
|
Sep 13
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
83,178
+0.08%
|
$1,913,094
$23.5 P/Share
|
|
Sep 10
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
30,000
+0.06%
|
$750,000
$25.11 P/Share
|
|
Sep 09
2021
|
Terrie Curran Director |
SELL
Open market or private sale
|
Direct |
4,850
-100.0%
|
$121,250
$25.58 P/Share
|
|
Sep 09
2021
|
Terrie Curran Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,850
+50.0%
|
$33,950
$7.65 P/Share
|
|
Sep 09
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,000
+0.07%
|
$925,000
$25.52 P/Share
|
|
Sep 08
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
21,902
+0.04%
|
$547,550
$25.74 P/Share
|
|
Sep 07
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
33,200
+0.03%
|
$863,200
$26.6 P/Share
|
|
Sep 03
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
31,200
+0.03%
|
$842,400
$27.02 P/Share
|
|
Sep 02
2021
|
Terrie Curran Director |
SELL
Open market or private sale
|
Direct |
37,135
-100.0%
|
$928,375
$25.03 P/Share
|
|
Sep 02
2021
|
Terrie Curran Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,135
+50.0%
|
$259,945
$7.65 P/Share
|
|
Sep 02
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
63,102
+0.04%
|
$1,640,652
$26.22 P/Share
|
|
Sep 01
2021
|
Terrie Curran Director |
SELL
Open market or private sale
|
Direct |
11,373
-100.0%
|
$284,325
$25.0 P/Share
|
|
Sep 01
2021
|
Terrie Curran Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,373
+50.0%
|
$79,611
$7.65 P/Share
|
|
Sep 01
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,000
+0.08%
|
$960,000
$24.83 P/Share
|
|
Aug 31
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
39,000
+0.08%
|
$936,000
$24.28 P/Share
|
|
Aug 30
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
70,000
+0.14%
|
$1,610,000
$23.92 P/Share
|
|
Aug 30
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,000
-10.92%
|
$504,000
$24.05 P/Share
|
|
Aug 30
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+9.84%
|
$147,000
$7.78 P/Share
|
|
Aug 27
2021
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,978
-1.14%
|
$43,516
$22.69 P/Share
|
|
Aug 27
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,038
+0.08%
|
$851,874
$23.17 P/Share
|
|
Aug 26
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,000
+0.08%
|
$880,000
$22.67 P/Share
|
|
Aug 25
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
28,709
+0.06%
|
$631,598
$22.44 P/Share
|
|
Aug 24
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
34,299
+0.07%
|
$754,578
$22.37 P/Share
|
|
Aug 23
2021
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
55,447
+0.06%
|
$1,219,834
$22.29 P/Share
|